These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38413239)

  • 1. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.
    Paller AS; Green LJ; Silverberg N; Stripling S; Cartwright M; Enloe C; Wells N; Kowalewski EK; Maeda-Chubachi T
    Pediatr Dermatol; 2024; 41(3):438-444. PubMed ID: 38413239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials.
    Sugarman JL; Hebert A; Browning JC; Paller AS; Stripling S; Green LJ; Cartwright M; Enloe C; Wells N; Maeda-Chubachi T
    J Am Acad Dermatol; 2024 Feb; 90(2):299-308. PubMed ID: 37804936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.
    Browning JC; Enloe C; Cartwright M; Hebert A; Paller AS; Hebert D; Kowalewski EK; Maeda-Chubachi T
    JAMA Dermatol; 2022 Aug; 158(8):871-878. PubMed ID: 35830173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of topical nitric oxide-releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta-analysis of randomized controlled trials.
    Pera Calvi I; R Marques I; Cruz SA; Mesquita YLL; Padrao EMH; Souza RM; Brown A; Caçador DGV; Poppe LM; Lopes Almeida Gomes L
    Pediatr Dermatol; 2023; 40(6):1060-1063. PubMed ID: 37721050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial.
    Hebert AA; Siegfried EC; Durham T; de León EN; Reams T; Messersmith E; Maeda-Chubachi T
    J Am Acad Dermatol; 2020 Apr; 82(4):887-894. PubMed ID: 31586600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum.
    Cartwright M; Enloe C; Stripling S; Maeda-Chubachi T
    J Drugs Dermatol; 2022 Oct; 21(10):1104-1110. PubMed ID: 36219053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results.
    Browning JC; Cartwright M; Thorla I; Martin SA; Olayinka-Amao O; Maeda-Chubachi T
    Am J Clin Dermatol; 2023 Jan; 24(1):119-133. PubMed ID: 36287306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology.
    Ward BM; Riccio DA; Cartwright M; Maeda-Chubachi T
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
    JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    Eichenfield LF; Siegfried E; Kwong P; McBride M; Rieger J; Glover D; Willson C; Davidson M; Burnett P; Olivadoti M
    Am J Clin Dermatol; 2021 Mar; 22(2):257-265. PubMed ID: 33599960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berdazimer Topical Gel, 10.3%: First Approval.
    Keam SJ
    Drugs; 2024 Mar; 84(3):363-368. PubMed ID: 38409574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
    Niazi S; Brabec B; Anschutz L; Willson C; Davidson M; Burnett P
    J Drugs Dermatol; 2021 Jan; 20(1):70-75. PubMed ID: 33400412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the correlation between molluscum contagiosum and atopic dermatitis in children.
    Seize MB; Ianhez M; Cestari Sda C
    An Bras Dermatol; 2011; 86(4):663-8. PubMed ID: 21987130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for cutaneous molluscum contagiosum.
    van der Wouden JC; van der Sande R; Kruithof EJ; Sollie A; van Suijlekom-Smit LW; Koning S
    Cochrane Database Syst Rev; 2017 May; 5(5):CD004767. PubMed ID: 28513067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical remission of disseminated molluscum contagiosum infection in a patient with atopic dermatitis treated with dupilumab.
    Elosua-González M; Rosell-Díaz Á; Alfageme-Roldán F; Sigüenza-Sanz M; Roustan-Gullón G
    An Bras Dermatol; 2022; 97(3):358-361. PubMed ID: 35307242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study.
    Syed TA; Lundin S; Ahmad M
    Dermatology; 1994; 189(1):65-8. PubMed ID: 8003791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of topical application of 15% and 10% potassium hydroxide for the treatment of Molluscum contagiosum.
    Teixidó C; Díez O; Marsal JR; Giner-Soriano M; Pera H; Martinez M; Galindo-Ortego G; Schoenenberger JA; Real J; Cruz I; Morros R
    Pediatr Dermatol; 2018 May; 35(3):336-342. PubMed ID: 29479727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.